




SUPPLEMENTARY FIGURES




Supplementary Figure 1. eGFP expression in 3xTg-AD mice orally administered with LAB (pExu:egfp). Detection of eGFP in the intestine (ileum (A) and duodenum (B) portions) and brain (C, D) of 3xTg-AD mice. Fluorescence in intestinal cells was detected 6 h after the treatment and fluorescence in the brain was evidenced from 48 h to 72 h after gavage.



Supplementary Figure 2. Immunodetection of the m-p62 protein in mesenteric lymph nodes of 3xTg-AD mice. Mesenteric lymph nodes of p62-LAB treated 3xTg-AD mice (panel D) show a strong positivity of large groups of cells (morphologically related to mature macrophages, with some mononuclear cells). An anti-murine p62 antibody was used in the immunoassay (10x, Bar= 250µm) (*p<0.05 and **p<0.01 vs T0, #p<0.05 and ##p<0.01 vs C, \$\$p<0.05 vs LAB).



Supplementary Figure 3. Immunodetection of amyloid peptides in brain sections of 3xTg-AD mice using the anti-6E10 antibody. Immunohistochemical analysis of brain sections (magnifications 2× and 10×) from T0, C, LAB and p62-LAB groups stained with the 6E10 antibody, specific for A β (1–40) and A β (1–42) peptides and the amyloid precursor protein, and relative immunoreactivity (* p<0.05 and ** p<0.01 vs T0, # p<0.05 and ## p<0.01 vs C, § p<0.05 vs LAB).



Supplementary Figure 4. Plasma concentrations of gut hormones in 3xTg-AD mice. ELISA tests were performed following the instructions of the manufacturer (see Materials and Methods for further details). Data points marked with an asterisk are statistically significant compared to untreated 8-weeks-old mice (T0, * $p < 0.05$).